Headquartered in Waltham, MA Fiscal year ends December NASDAQ: KLRA kailera.com
Kailera Therapeutics is a clinical-stage biotechnology company focused on developing GLP-1-based therapeutics for the treatment of obesity. The company is advancing a diversified pipeline of four clinical-stage product candidates that span single-, dual-, and triple-agonist mechanisms with both oral and injectable formulations. Its lead candidate, ribupatide injection (KAI-9531), is a once-weekly injectable GLP-1/GIP receptor dual agonist in global Phase 3 trials. Kailera is also developing a once-daily oral formulation of ribupatide, KAI-7535 (an oral small molecule GLP-1 receptor agonist in Phase 2), and KAI-4729 (a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist approaching Phase 1). The company's product candidates are licensed from Hengrui Pharma, which conducts parallel clinical programs primarily in China. Kailera trades on Nasdaq under the ticker KLRA and generates no product revenue as a pre-commercial entity. Updated
Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to…
Kailera Therapeutics is a clinical-stage biotechnology company focused on developing GLP-1-based therapeutics for the treatment of obesity.
The Wall Street consensus 12-month price target for KLRA is $42.40.
